Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Association of comorbidity burden with cause-specific survival after CAR T therapy for large B-cell lymphoma.

Leukemia & lymphoma·2026

Same author

A phase 1 study of R-GDP-venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18).

Blood neoplasia·2026

Same author

Detection and classification of lymphoma from cell-free methylome data.

NPJ precision oncology·2026

Same author

Intraperitoneal administration of NK-92 improves survival in xenografts of early and established ovarian cancer models.

PloS one·2026

Same author

Targeted therapy in early-stage classical Hodgkin lymphoma.

Blood·2026

Same author

Relapsed classic Hodgkin lymphoma; should all patients receive an autologous stem cell transplant? - the PRO.

Haematologica·2026

Search research articles

Related Experiment Video

Updated: Jul 7, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Salvage therapy for relapsed/refractory diffuse large B cell lymphoma.

Tara Seshadri¹, John Kuruvilla, Michael Crump

¹Autologous Blood and Marrow Transplant Program, Princess Margaret Hospital, Toronto, Ontario, Canada. Tara.Seshadri@uhn.on.ca

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation

|February 16, 2008

Summary

This summary is machine-generated.

Diffuse large B cell lymphoma (DLBCL) frequently relapses after initial treatment. Current prognostic markers and salvage therapies for relapsed DLBCL are reviewed, highlighting the need for novel treatments.

Related Experiment Videos

Last Updated: Jul 7, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Area of Science:

Hematology
Oncology
Immunology

Background:

Diffuse large B cell lymphoma (DLBCL) is an aggressive lymphoma with significant heterogeneity.
Up to 50% of patients experience relapse after standard chemoimmunotherapy.
Existing prognostic tools like the International Prognostic Index (IPI) offer limited predictive power for relapsed disease.

Purpose of the Study:

To review prognostic markers for relapsed/refractory DLBCL.
To summarize current salvage chemotherapy and autologous hematopoietic cell transplantation (aHCT) approaches.
To discuss emerging novel therapies for relapsed DLBCL.

Main Methods:

Literature review of prognostic markers.
Analysis of current salvage chemotherapy regimens.
Evaluation of autologous hematopoietic cell transplantation (aHCT) in relapsed DLBCL.
Discussion of novel therapeutic strategies.

Main Results:

The International Prognostic Index (IPI) provides prognostic information but lacks predictive biologic markers.
Salvage chemotherapy followed by aHCT is standard for chemotherapy-sensitive relapsed DLBCL.
No universally standard salvage chemotherapy regimen exists.
The role of immunotherapy in relapsed DLBCL requires further investigation.

Conclusions:

Prognostic markers for relapsed/refractory DLBCL require further molecular clarification.
Current management relies on salvage chemotherapy and aHCT, with ongoing research into optimal regimens.
Novel therapeutic approaches are crucial for improving outcomes in relapsed DLBCL.